
Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo
来源:Reuters发布于 2026-11-03
Teva Pharmaceutical Industries expects to grow in 2027 despite the US inflation reduction act that will cap prices for its top branded drug Austedo to treat Huntington's Disease and Tardive Dyski...
相关标的:TEVA
本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。